{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:18:17Z","timestamp":1765887497277},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,4,9]],"date-time":"2013-04-09T00:00:00Z","timestamp":1365465600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s11864-013-0232-x","type":"journal-article","created":{"date-parts":[[2013,4,8]],"date-time":"2013-04-08T06:38:48Z","timestamp":1365403128000},"page":"212-223","source":"Crossref","is-referenced-by-count":22,"title":["Treatment of Peripheral T-cell Lymphoma: Are We Data Driven or Driving the Data?"],"prefix":"10.1007","volume":"14","author":[{"given":"Matthew A.","family":"Lunning","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,9]]},"reference":[{"issue":"5","key":"232_CR1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood. 1994;84(5):1361\u201392.","journal-title":"Blood"},{"issue":"25","key":"232_CR2","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330. The largest retrospective review on the prevalence and outcomes of PTCL and is broken down further by WHO subtypes. This article also reenforced the utility of the IPI as a prognostic index in PTCL as well as brought to question whether an antracycline based regimen is imparitive in the initial management of PTCL.","journal-title":"J Clin Oncol"},{"issue":"4","key":"232_CR3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.blre.2007.03.001","volume":"21","author":"KJ Savage","year":"2007","unstructured":"Savage KJ. Peripheral T-cell lymphomas. Blood Rev. 2007;21(4):201\u201316.","journal-title":"Blood Rev"},{"key":"232_CR4","doi-asserted-by":"crossref","unstructured":"Voss MH, Lunning MA, Maragulia JC, et al. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic t-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk. 2012. doi: 10.1016\/j.clml.2012.09.002 .","DOI":"10.1016\/j.clml.2012.09.002"},{"key":"232_CR5","doi-asserted-by":"crossref","unstructured":"Federico M, Rudiger T, Bellei M, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2012. doi: 10.1200\/JCO.2011.37.3647 .","DOI":"10.1200\/JCO.2011.37.3647"},{"issue":"6","key":"232_CR6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2008.77","volume":"22","author":"AL Feldman","year":"2008","unstructured":"Feldman AL, Sun DX, Law ME, et al. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia. 2008;22(6):1139\u201343.","journal-title":"Leukemia"},{"issue":"1","key":"232_CR7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/leu.2009.198","volume":"24","author":"RA Wilcox","year":"2010","unstructured":"Wilcox RA, Sun DX, Novak A, Dogan A, Ansell SM, Feldman AL. Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin\u2019s lymphoma cell lines. Leukemia. 2010;24(1):229\u201332.","journal-title":"Leukemia"},{"issue":"10","key":"232_CR8","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood.V78.10.2686.2686","volume":"78","author":"TJ Fitzgerald","year":"1991","unstructured":"Fitzgerald TJ, Neale GA, Raimondi SC, Goorha RM. c-tal, a helix-loop-helix protein, is juxtaposed to the T-cell receptor-beta chain gene by a reciprocal chromosomal translocation: t(1;7)(p32;q35). Blood. 1991;78(10):2686\u201395.","journal-title":"Blood"},{"issue":"12","key":"232_CR9","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T-cell lymphoma project. Blood. 2011;117(12):3402\u20138.","journal-title":"Blood"},{"issue":"2","key":"232_CR10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2214\/AJR.09.3665","volume":"195","author":"J Feeney","year":"2010","unstructured":"Feeney J, Horwitz S, Gonen M, Schoder H. Characterization of T-cell lymphomas by FDG PET\/CT. AJR Am J Roentgenol. 2010;195(2):333\u201340.","journal-title":"AJR Am J Roentgenol"},{"issue":"11","key":"232_CR11","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood.V93.11.3913","volume":"93","author":"RD Gascoyne","year":"1999","unstructured":"Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93(11):3913\u201321.","journal-title":"Blood"},{"issue":"12","key":"232_CR12","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK\u2009+\u2009ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-cell lymphoma project. Blood. 2008;111(12):5496\u2013504.","journal-title":"Blood"},{"issue":"7","key":"232_CR13","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474\u20139.","journal-title":"Blood"},{"issue":"14","key":"232_CR14","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","volume":"30","author":"H Katsuya","year":"2012","unstructured":"Katsuya H, Yamanaka T, Ishitsuka K, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma. J Clin Oncol. 2012;30(14):1635\u201340.","journal-title":"J Clin Oncol"},{"issue":"3","key":"232_CR15","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s12032-011-0030-x","volume":"29","author":"JJ Huang","year":"2012","unstructured":"Huang JJ, Zhu YJ, Xia Y, et al. A novel prognostic model for extranodal natural killer\/T-cell lymphoma. Med Oncol. 2012;29(3):2183\u201390.","journal-title":"Med Oncol"},{"issue":"3","key":"232_CR16","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1007\/s12032-011-0011-0","volume":"29","author":"PP Xu","year":"2012","unstructured":"Xu PP, Wang Y, Shen Y, Wang L, Shen ZX, Zhao WL. Prognostic factors of Chinese patients with T\/NK-cell lymphoma: a single institution study of 170 patients. Med Oncol. 2012;29(3):2176\u201382.","journal-title":"Med Oncol"},{"issue":"12","key":"232_CR17","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.6004\/jnccn.2012.0155","volume":"10","author":"AD Zelenetz","year":"2012","unstructured":"Zelenetz AD, Wierda WG, Abramson JS, et al. Non-Hodgkin\u2019s lymphomas, version 3.2012. J Natl Compr Canc Netw. 2012;10(12):1487\u201398.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"232_CR18","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","volume":"15","author":"KJ Savage","year":"2004","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single north american institution by the WHO classification. Ann Oncol. 2004;15(10):1467\u201375.","journal-title":"Ann Oncol"},{"issue":"18","key":"232_CR19","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the german high-grade non-hodgkin lymphoma study group. Blood. 2010;116(18):3418\u201325.","journal-title":"Blood"},{"issue":"25","key":"232_CR20","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093\u20139. The largest study to date demonstrating the outcomes of autologous stecm cell transplant in first chemosensitive remisson in patients with the most common subtypes of PTCL (PTCL-NOS, AITL, and ALCL ALK negative). This study deferentiated induction regimens based on age (CHOEP vs CHOP). Patients with ALCL ALK negative did very well with this regimen. Mobilization following CHOEP did not appear to be an issue.","journal-title":"J Clin Oncol"},{"key":"232_CR21","doi-asserted-by":"crossref","unstructured":"Mahadevan D, Unger JM, Spier CM, et al. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest oncology group study S0350. Cancer. 2012. doi: 10.1002\/cncr.27733 . A prospective study utilizing a non-anthracycline based regimen in newly diagnosed and relapsed\/refractory PTCL. The results demonstrated a low ORR (29\u00a0%) and a short PFS of 14\u00a0months in newly diagnosed patients.","DOI":"10.1002\/cncr.27733"},{"issue":"2","key":"232_CR22","doi-asserted-by":"crossref","first-page":"e4420","DOI":"10.1371\/journal.pone.0004420","volume":"4","author":"L Ratner","year":"2009","unstructured":"Ratner L, Harrington W, Feng X, et al. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. PLoS One. 2009;4(2):e4420.","journal-title":"PLoS One"},{"issue":"34","key":"232_CR23","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","volume":"25","author":"K Tsukasaki","year":"2007","unstructured":"Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan clinical oncology group study JCOG9801. J Clin Oncol. 2007;25(34):5458\u201364.","journal-title":"J Clin Oncol"},{"issue":"7","key":"232_CR24","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","volume":"22","author":"HC Kluin-Nelemans","year":"2011","unstructured":"Kluin-Nelemans HC, van Marwijk KM, Lugtenburg PJ, et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol. 2011;22(7):1595\u2013600.","journal-title":"Ann Oncol"},{"key":"232_CR25","doi-asserted-by":"crossref","unstructured":"d\u2019Amore FLS, Gmes da Silva M et al. First interim efficacy and safety analysis of an international phase III randomized trial in newly diagnosed systemic peripheral T-cell lymphoma treated with chemotherapy with or without alemtuzumab and consolidated by high dose therapy. Blood (ASH Abstract #57). 2012.","DOI":"10.1182\/blood.V120.21.57.57"},{"issue":"7","key":"232_CR26","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3109\/10428194.2011.572322","volume":"52","author":"D Ennishi","year":"2011","unstructured":"Ennishi D, Maeda Y, Fujii N, et al. Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer\/T-cell lymphoma, nasal type. Leuk Lymphoma. 2011;52(7):1255\u201361.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"232_CR27","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2012-03-414490","volume":"120","author":"T Ishida","year":"2012","unstructured":"Ishida T, Hishizawa M, Kato K, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120(8):1734\u201341.","journal-title":"Blood"},{"issue":"1","key":"232_CR28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2012-07-444372","volume":"121","author":"H Itonaga","year":"2013","unstructured":"Itonaga H, Tsushima H, Taguchi J, et al. Treatment of relapsed adult T-cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation: the nagasaki transplant group experience. Blood. 2013;121(1):219\u201325.","journal-title":"Blood"},{"issue":"6","key":"232_CR29","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdn751","volume":"20","author":"GS Falchook","year":"2009","unstructured":"Falchook GS, Vega F, Dang NH, et al. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol. 2009;20(6):1080\u20135.","journal-title":"Ann Oncol"},{"issue":"33","key":"232_CR30","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","volume":"29","author":"M Yamaguchi","year":"2011","unstructured":"Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-cell tumor study group study. J Clin Oncol. 2011;29(33):4410\u20136. The first prospective study of a asparaginase based regimen (SMILE) in relapsed\/refractory and newly diagnosed advanced stage NK\/TCL patients. This study demonstrated a promising CR rate of 40\u00a0% in advanced stage patients. This regimen also demonstrated the ability to salvage patients with relapsed or refractory disease who had not seen asparaginase in the past highlighting the unique sensitivity of asparaginase in NK\/TCL.","journal-title":"J Clin Oncol"},{"issue":"1","key":"232_CR31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2005.03.2573","volume":"24","author":"YX Li","year":"2006","unstructured":"Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma. J Clin Oncol. 2006;24(1):181\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"232_CR32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1023\/A:1011144911781","volume":"12","author":"WS Kim","year":"2001","unstructured":"Kim WS, Song SY, Ahn YC, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer\/T-cell lymphoma? Ann Oncol. 2001;12(3):349\u201352.","journal-title":"Ann Oncol"},{"issue":"6","key":"232_CR33","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/10428190902887571","volume":"50","author":"AA Phillips","year":"2009","unstructured":"Phillips AA, Willim RD, Savage DG, et al. A multi-institutional experience of autologous stem cell transplantation in North American patients with human T-cell lymphotropic virus type-1 adult T-cell leukemia\/lymphoma suggests ineffective salvage of relapsed patients. Leuk Lymphoma. 2009;50(6):1039\u201342.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"232_CR34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.bmt.1701533","volume":"23","author":"K Tsukasaki","year":"1999","unstructured":"Tsukasaki K, Maeda T, Arimura K, et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia\/lymphoma: a case report and review of the literature. Bone Marrow Transplant. 1999;23(1):87\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"232_CR35","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3109\/10428190109097733","volume":"42","author":"J Watanabe","year":"2001","unstructured":"Watanabe J, Kondo H, Hatake K. Autologous stem cell transplantations for recurrent adult T cell leukaemia\/lymphoma using highly purified CD34+ cells derived from cryopreserved peripheral blood stem cells. Leuk Lymphoma. 2001;42(5):1115\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"232_CR36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000058317","volume":"107","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara H, Arima N, Akasaki Y, et al. Interferon-alpha therapy following autologous peripheral blood stem cell transplantation for adult T cell leukemia\/lymphoma. Acta Haematol. 2002;107(4):213\u20139.","journal-title":"Acta Haematol"},{"issue":"3","key":"232_CR37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2141.2007.06658.x","volume":"139","author":"OA O\u2019Connor","year":"2007","unstructured":"O\u2019Connor OA, Hamlin PA, Portlock C, et al. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol. 2007;139(3):425\u20138.","journal-title":"Br J Haematol"},{"issue":"26","key":"232_CR38","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","volume":"27","author":"OA O\u2019Connor","year":"2009","unstructured":"O\u2019Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009;27(26):4357\u201364.","journal-title":"J Clin Oncol"},{"issue":"3","key":"232_CR39","first-page":"718","volume":"8","author":"V Sandor","year":"2002","unstructured":"Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002;8(3):718\u201328.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"232_CR40","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"RL Piekarz","year":"2011","unstructured":"Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827\u201334.","journal-title":"Blood"},{"issue":"9","key":"232_CR41","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182\u20139. The seminal aritcle which led to the FDA approval of pralatrexate in relapsed\/refractory PTCL. Of note, AITL as a distinct subtype had a lower ORR (8\u00a0%) to pralatrexate compared to PTCL-NOS and ALCL ALK negative.","journal-title":"J Clin Oncol"},{"issue":"6","key":"232_CR42","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631\u20136.","journal-title":"J Clin Oncol"},{"key":"232_CR43","doi-asserted-by":"crossref","unstructured":"Fanale MASA, Foereo-Torres A, Bartlett NL, Advani RJ, Pro B, et al. Brentuximab vedotin administered concurrently with multi-agent chemotherapy as frontline treatment of ALCL and other CD30-positive mature T-cell and NK-cell lymphoma. Blood (ASH Abstract #60). 2012.","DOI":"10.1182\/blood.V120.21.60.60"},{"issue":"17","key":"232_CR44","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2001.19.17.3766","volume":"19","author":"J Rodriguez","year":"2001","unstructured":"Rodriguez J, Munsell M, Yazji S, et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol. 2001;19(17):3766\u201370.","journal-title":"J Clin Oncol"},{"issue":"12","key":"232_CR45","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","volume":"14","author":"J Rodriguez","year":"2003","unstructured":"Rodriguez J, Caballero MD, Gutierrez A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol. 2003;14(12):1768\u201375.","journal-title":"Ann Oncol"},{"issue":"3","key":"232_CR46","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.bmt.1705712","volume":"40","author":"SD Smith","year":"2007","unstructured":"Smith SD, Bolwell BJ, Rybicki LA, et al. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant. 2007;40(3):239\u201343.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"232_CR47","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","volume":"22","author":"P Corradini","year":"2004","unstructured":"Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22(11):2172\u20136.","journal-title":"J Clin Oncol"},{"issue":"14","key":"232_CR48","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","volume":"26","author":"S Gouill Le","year":"2008","unstructured":"Le Gouill S, Milpied N, Buzyn A, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol. 2008;26(14):2264\u201371.","journal-title":"J Clin Oncol"},{"issue":"7","key":"232_CR49","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","volume":"22","author":"ED Jacobsen","year":"2011","unstructured":"Jacobsen ED, Kim HT, Ho VT, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides\/Sezary syndrome. Ann Oncol. 2011;22(7):1608\u201313.","journal-title":"Ann Oncol"},{"issue":"6","key":"232_CR50","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3109\/10428194.2011.645818","volume":"53","author":"JD Goldberg","year":"2012","unstructured":"Goldberg JD, Chou JF, Horwitz S, et al. Long-term survival in patients with peripheral T-cell non-hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2012;53(6):1124\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"232_CR51","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P, Rudiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27(1):106\u201313.","journal-title":"J Clin Oncol"},{"issue":"9","key":"232_CR52","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","volume":"20","author":"P Corradini","year":"2006","unstructured":"Corradini P, Tarella C, Zallio F, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20(9):1533\u20138.","journal-title":"Leukemia"},{"issue":"5","key":"232_CR53","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","volume":"19","author":"S Mercadal","year":"2008","unstructured":"Mercadal S, Briones J, Xicoy B, et al. Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008;19(5):958\u201363.","journal-title":"Ann Oncol"},{"issue":"1","key":"232_CR54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","volume":"79","author":"J Rodriguez","year":"2007","unstructured":"Rodriguez J, Conde E, Gutierrez A, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the gel-tamo study group. Eur J Haematol. 2007;79(1):32\u20138.","journal-title":"Eur J Haematol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-013-0232-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-013-0232-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-013-0232-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T01:24:17Z","timestamp":1595640257000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-013-0232-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,9]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["232"],"URL":"https:\/\/doi.org\/10.1007\/s11864-013-0232-x","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,9]]}}}